Baxter International Divests Kidney Care Segment to Carlyle Group
Tuesday, 13 August 2024, 05:37
Baxter International Sells Kidney Care Segment
Baxter International BAX is divesting its kidney care segment
Details of the Transaction
- Sale Amount: $3.8 billion
- Buyer: Carlyle Group CG
- Focus: Baxter aims to concentrate on core growth areas
Implications for Baxter and Carlyle
- Quality Improvement: The sale is part of Baxter's strategy to allocate resources towards innovation.
- Portfolio Expansion: Carlyle is adding significant value to its investment mix through this acquisition.
This divestiture not only reflects Baxter's intent to streamline operations but also strengthens Carlyle's healthcare portfolio in a rapidly evolving market.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.